Stenn K S
J Invest Dermatol. 1987 Jul;89(1):59-63. doi: 10.1111/1523-1747.ep12580392.
Earlier studies have shown that epibolin, a glycoprotein in human plasma, identical to preparations from other laboratories referred to as serum spreading factor and vitronectin, requires a second plasma activity in order to support maximal primary epidermal cell spreading. This plasma fraction, referred to as coepibolin, alone supports no cell spreading but potentiates the activity of epibolin by at least 5-10 times. Studies reported here indicate that coepibolin activity associates with one plasma fraction, it cannot be substituted by commercial preparations of ovalbumin, soybean trypsin inhibitor, or hemoglobin, but it can be substituted by commercial bovine or human serum albumin. The activity purified to electrophoretic homogeneity comigrates with, and shows antigenic properties of albumin. Under the assay conditions coepibolin affects the extent and morphology of cell spreading: in the presence of epibolin plus coepibolin cells assume a more polar orientation than in epibolin alone. For its maximal effect coepibolin must be present continuously in the early phases of cell spreading.
早期研究表明，表皮生成素是一种存在于人体血浆中的糖蛋白，与其他实验室制备的被称为血清扩散因子和玻连蛋白的制剂相同，它需要第二种血浆活性物质才能支持原代表皮细胞的最大程度扩散。这种血浆成分被称为协同表皮生成素，单独存在时不能支持细胞扩散，但能将表皮生成素的活性增强至少5至10倍。此处报道的研究表明，协同表皮生成素的活性与一种血浆成分相关，它不能被商业制备的卵清蛋白、大豆胰蛋白酶抑制剂或血红蛋白替代，但可以被商业牛血清白蛋白或人血清白蛋白替代。纯化至电泳均一性的该活性物质与白蛋白共迁移，并显示出白蛋白的抗原特性。在检测条件下，协同表皮生成素会影响细胞扩散的程度和形态：在存在表皮生成素和协同表皮生成素的情况下，细胞比仅存在表皮生成素时呈现出更极性的取向。为了发挥其最大作用，协同表皮生成素必须在细胞扩散的早期阶段持续存在。
